FDA ap­proves Sanofi's fac­tor VI­II he­mo­phil­ia A drug

Sanofi nabbed an FDA ap­proval for its new he­mo­phil­ia A ther­a­py, efane­soc­tocog al­fa, on Wednes­day evening, ac­cord­ing to FDA doc­u­ments.

The new­ly ap­proved drug — which has the fac­tor VI­II fo­cus spelled out in­side its brand­ed name, Al­tuvi­i­io — works to re­place the miss­ing or de­fec­tive fac­tor VI­II in he­mo­phil­ia A in a once-week­ly treat­ment. It wasn’t im­me­di­ate­ly clear Thurs­day morn­ing how Sanofi plans to price the drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.